Literature DB >> 22588899

CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas.

Felix Sahm1, Christian Koelsche, Jochen Meyer, Stefan Pusch, Kerstin Lindenberg, Wolf Mueller, Christel Herold-Mende, Andreas von Deimling, Christian Hartmann.   

Abstract

CIC and FUBP1 mutations have recently been detected in oligodendrogliomas but not in oligoastrocytomas. However, allelic losses in the regions on chromosomal arms 19q and 1p harboring CIC and FUBP1 are a common feature of both, oligodendrogliomas and oligoastrocytomas. To resolve this discrepancy, we analyzed CIC and FUBP1 mutations in a set of primary brain tumors including 18 oligodendrogliomas and 42 oligoastrocytomas. In addition, we analyzed 10 astrocytomas and 16 glioblastomas with allelic losses on 19q as well as a set of 12 medulloblastomas for CIC mutations. CIC mutations were found in 15/18 oligodendrogliomas, 14/42 oligoastrocytomas and 3/10 preselected astrocytomas. With the exception of a single case, all CIC mutations occurred in tumors with combined 1p/19q losses. In contrast to oligodendrogliomas where CIC mutations were always detected along with 1p/19q co-deletion, CIC mutations were only found in 52 % of the 1p/19q co-deleted oligoastrocytomas. FUBP1 mutations were detected in 7/61 tumors, all presenting with CIC mutations. FUBP1 mutations appear to cluster in the DNA binding domain spanning exons 5-14. CIC and FUBP1 mutations exclusively occurred in presence of either IDH1 or IDH2 mutations. Our data confirm CIC and FUBP1 mutations in oligodendrogliomas and demonstrate the presence of these mutations in oligoastrocytomas.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22588899     DOI: 10.1007/s00401-012-0993-5

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  51 in total

Review 1.  The evolving molecular genetics of low-grade glioma.

Authors:  Sriram Venneti; Jason T Huse
Journal:  Adv Anat Pathol       Date:  2015-03       Impact factor: 3.875

2.  Sarcomas With CIC-rearrangements Are a Distinct Pathologic Entity With Aggressive Outcome: A Clinicopathologic and Molecular Study of 115 Cases.

Authors:  Cristina R Antonescu; Adepitan A Owosho; Lei Zhang; Sonja Chen; Kemal Deniz; Joseph M Huryn; Yu-Chien Kao; Shih-Chiang Huang; Samuel Singer; William Tap; Inga-Marie Schaefer; Christopher D Fletcher
Journal:  Am J Surg Pathol       Date:  2017-07       Impact factor: 6.394

3.  Minibrain and Wings apart control organ growth and tissue patterning through down-regulation of Capicua.

Authors:  Liu Yang; Sayantanee Paul; Kenneth G Trieu; Lucas G Dent; Francesca Froldi; Marta Forés; Kaitlyn Webster; Kellee R Siegfried; Shu Kondo; Kieran Harvey; Louise Cheng; Gerardo Jiménez; Stanislav Y Shvartsman; Alexey Veraksa
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-06       Impact factor: 11.205

Review 4.  A clinical perspective on the 2016 WHO brain tumor classification and routine molecular diagnostics.

Authors:  Martin J van den Bent; Michael Weller; Patrick Y Wen; Johan M Kros; Ken Aldape; Susan Chang
Journal:  Neuro Oncol       Date:  2017-05-01       Impact factor: 12.300

5.  The splicing factor FUBP1 is required for the efficient splicing of oncogene MDM2 pre-mRNA.

Authors:  Aishwarya G Jacob; Ravi K Singh; Fuad Mohammad; Thomas W Bebee; Dawn S Chandler
Journal:  J Biol Chem       Date:  2014-05-05       Impact factor: 5.157

Review 6.  Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice.

Authors:  Michael Weller; Roger Stupp; Monika E Hegi; Martin van den Bent; Joerg C Tonn; Marc Sanson; Wolfgang Wick; Guido Reifenberger
Journal:  Neuro Oncol       Date:  2012-09       Impact factor: 12.300

7.  ZEB1 expression is increased in IDH1-mutant lower-grade gliomas.

Authors:  Cody L Nesvick; Chao Zhang; Nancy A Edwards; Blake K Montgomery; Michaela Lee; Chunzhang Yang; Herui Wang; Dongwang Zhu; John D Heiss; Marsha J Merrill; Abhik Ray-Chaudhury; Zhengping Zhuang
Journal:  J Neurooncol       Date:  2016-08-27       Impact factor: 4.130

8.  Recurrent CIC Gene Abnormalities in Angiosarcomas: A Molecular Study of 120 Cases With Concurrent Investigation of PLCG1, KDR, MYC, and FLT4 Gene Alterations.

Authors:  Shih-Chiang Huang; Lei Zhang; Yun-Shao Sung; Chun-Liang Chen; Yu-Chien Kao; Narasimhan P Agaram; Samuel Singer; William D Tap; Sandra D'Angelo; Cristina R Antonescu
Journal:  Am J Surg Pathol       Date:  2016-05       Impact factor: 6.394

Review 9.  Glioma diagnostics and biomarkers: an ongoing challenge in the field of medicine and science.

Authors:  Fred H Hochberg; Nadia A Atai; David Gonda; Michael S Hughes; Brolin Mawejje; Leonora Balaj; Robert S Carter
Journal:  Expert Rev Mol Diagn       Date:  2014-05       Impact factor: 5.225

Review 10.  Emerging biomarkers in anaplastic oligodendroglioma: implications for clinical investigation and patient management.

Authors:  Solmaz Sahebjam; Mairéad G McNamara; Warren P Mason
Journal:  CNS Oncol       Date:  2013-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.